NCT02015819 2021-10-20
Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas
City of Hope Medical Center
Phase 1 Completed
Clinical Trials
9 trialsNCT04327011 2020-03-30
A Continuation Protocol for Patients Previously Enrolled in a Study of Toca 511
Tocagen Inc.
Phase 1 Terminated
NCT02414165 2020-02-07
Toca5
Tocagen Inc.
Phase 2/3 Terminated
NCT02576665 2020-02-07
A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)
Tocagen Inc.
Phase 1 Terminated
NCT01156584 2018-05-21
A Study of a Retroviral Replicating Vector Combined With a Prodrug Administered to Patients With Recurrent Malignant Glioma
Tocagen Inc.
Phase 1 Completed
NCT01470794 2018-05-21
Study of a Retroviral Replicating Vector Combined With a Prodrug to Treat Patients Undergoing Surgery for a Recurrent Malignant Brain Tumor
Tocagen Inc.
Phase 1 Completed
NCT01985256 2018-05-21
Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brain Tumor
Tocagen Inc.
Phase 1 Completed
NCT01172964 2017-11-09
A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas
City of Hope Medical Center
Phase 1 Completed
NCT03294486 2017-11-06
ONCOVIRAC
Assistance Publique - Hôpitaux de Paris
Phase 1/2 Unknown